FTSE MIB
33.910,12 -631,89 (-1,83%) Dow Jones
38.868,04 +69,05 (+0,18%) Nasdaq
17.192,53 +59,40 (+0,35%) Nikkei 225
39.134,79 +96,63 (+0,25%) Petrolio
77,43 -0,31 (-0,40%) Bitcoin EUR
62.294,39 -2.344,75 (-3,63%)
CRBP Jun 2024 60.000 call
| Chiusura precedente | 2,5000 |
| Aperto | 2,5000 |
| Denaro | 0,0000 |
| Domanda | 0,0000 |
| Prezzo d'esercizio | 60,00 |
| Scadenza | 2024-06-21 |
| Min-Max giorno | 2,5000 - 2,5000 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 68 |
GlobeNewswireCorbus Pharmaceuticals Presents the First Pre-Clinical Characterization of its Next Generation Nectin-4 ADC CRB-701
CRB-701 demonstrates a differentiated nonclinical profile relative to enfortumab vedotinEarly dose escalation clinical data supports differentiating features established pre-clinicallyThe company on schedule to initiate its US study in Q1-2024 NORWOOD, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company, today announced that a poster characterizing the pre-clinical validation of CRB-701, a next ge
- GlobeNewswire
Corbus Pharmaceuticals to Host Virtual ‘Meet the Expert’ Series (Session 2) on CRB-701 on October 10, 2023
NORWOOD, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced that it will host a Virtual ‘Meet the Expert’ event on the development of a next generation Nectin-4 antibody drug conjugate, focusing on opportunities and challenges for CRB-701, on Tuesday, October 10, 2023 at 10:30am ET. To register for the webinar, click here. The event will feature several Oncology experts Daniel P.
